APL 9

Drug Profile

APL 9

Alternative Names: APL9

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Peptides; Polyethylene glycols
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 02 Jul 2018 Apellis Pharmaceuticals terminates a phase I trial (In volunteers) due to safety reasons in Australia (SC) (ACTRN12616000862448)
  • 01 Nov 2017 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (In volunteers) in Australia (SC) (ACTRN12617001308381)
  • 18 Sep 2017 Apellis Pharmaceuticals plans a phase I trial for Paroxysmal nocturnal haemoglobinuria in Australia (ACTRN12617001308381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top